Distribution and delivery of labile blood products

被引：0
|
作者：
Roubinet, Francis [1 ]
机构：
[1] Etablissement Francais Sang Ctr Atlant, 50 Ave Marcel Dassault,BP 40661, F-37206 Tours 3, France
来源：
HEMATOLOGIE | 2010年 / 16卷 / 04期
关键词：
labile blood products delivery; labile blood products distribution; blood products depot;
D O I：
10.1684/hma.2010.0434
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The national organization of blood delivery allows to dispose of blood products necessary to patients everywhere in France. The delivery based on the respect of the immuno-hematological characteristics of the patients and their compatibilities with the blood products allows to assign a product to a patient. The delivery rules to apply for preventing any major transfusion related accident are simple and very precise.
引用
收藏
页码：302 / 309
页数：8
相关论文
共 50 条
  • [31] French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP)
    Chamfly, V
    TRANSFUSION SCIENCE, 1998, 19 (04): : 333 - 342
  • [32] Transfusion of labile blood products: How to inform patients serenely without scaring them?
    Villevieille, Thierry
    Fevre, Guillaume
    Sfez, Michel
    Raucoules-Aime, Marc
    Cabaud, Jean-Jacques
    ANESTHESIE & REANIMATION, 2020, 6 (04): : 353 - 355
  • [33] The practice evaluation of prescriptions in the French establishments of health (Berry) for deliveries of labile blood products
    Sapey, T.
    Poirier-Cajat, C.
    Desmaisons, C.
    Rongere, D.
    Sanceau, J.
    Lele, I.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2017, 24 (01) : 28 - 29
  • [34] Consequences of genetic diversity of human erythrovirus on infectious security of labile blood products and drugs derived from blood
    Servant-Delmas, A.
    Mercier, M.
    Lefrere, J. -J.
    Laperche, S.
    VIROLOGIE, 2008, 12 (06) : 419 - 427
  • [35] Use of Laboratory Robots for Transport and Delivery of Blood Products
    Lum, Gifford
    D'Amarino, Michael J.
    LABMEDICINE, 2009, 40 (09): : 517 - 522
  • [36] Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety
    Cazenave, Jean-Pierre
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2010, 194 (09): : 1707 - 1719
  • [37] Current prescription practices for labile blood products in France: An investigation by the french society of transfusion (SFTS).
    Rieux, C
    Bastuji-Garin, S
    Vicariot, M
    Waller, C
    Quaranta, JF
    Bierling, P
    Reyes, F
    BLOOD, 1999, 94 (10) : 121B - 121B
  • [38] Electronic prescription of Labile Blood Products: A cultural revolution by the APHM and EFS PACA-Corsica!
    Lassale, Bernard
    Izard, Caroline
    Coze, Carole
    Basset, Laurent
    Boissy, Lilian
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2025, 32 (01) : 44 - 47
  • [39] The difficulties of irradiation of labile blood products in low-income countries: An efficient and affordable alternative
    Naim, A.
    Bouanani, N.
    Krabech, M. A.
    Saidi, K.
    Elgoach, H.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2020, 27 (04) : 268 - 269
  • [40] A man with labile blood pressure
    Ma, Ronald C. W.
    Yiu, Kwok Hing
    Wong, Edward H. C.
    Liu, Kin Hung
    Chan, Joseph Y. S.
    Chow, Chun Chung
    Cockram, Clive S.
    PLOS MEDICINE, 2007, 4 (04): : 642 - 645
12345